Purpose Documentation of a wild-type (wt) KRAS gene in tumor has become mandatory for the prescription of anti-EGFR monoclonal antibodies in patients with colorectal cancer (CRC). Acquired KRAS mutations have seldom been reported in metastases from wt KRAS primary CRC. We report the Wrst case of multiple KRAS mutations acquired during the metastatic phase of CRC, and retrospectively reviewed all patients with CRC, in whom KRAS was analyzed in at least two tumor samples from distinct lesions. Methods Genomic DNA puriWed from paraYn-embedded tissues was used after histological quantiWcation of tumor tissue. The seven KRAS mutations located within codons 12 and 13 were screened using the allelic discrimination assay. Results A 35-year-old woman with CRC liver metastasis, resistant to all conventional cytotoxic agents, experienced for the Wrst time signiWcant tumor shrinkage while cetuximab was added, allowing hepatic resection. Further liver relapse occurred on cetuximab, but a new hepatic resection was attempted. No mutation in KRAS was detected in the primary colon tumor or in synchronous liver metastases. In contrast, in metachronous liver metastasis samples, two distinct mutations at codon 13 and 12 were detected. No acquired mutations were found in all the other 12 CRC cases with at least two serially performed KRAS analyses. Conclusions Our Wndings suggest that late switch in KRAS mutational status could occur more frequently than currently recognized and account for acquired resistance to anti-EGFR therapies. Prospective studies are warranted to better estimate the incidence of change in KRAS mutational status and assess their clinical relevance.
Introduction
Mutations of the KRAS gene have been recently shown to predict resistance to epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies [1] [2] [3] . KRAS wild type (wt) is now a standard requirement for prescription of anti-EGFR therapy in patients with metastatic colorectal cancer (mCRC) [4, 5] . Nevertheless, little is known about the evolution of the KRAS mutational status and subsequent gene mutations during the spontaneous course of disease progression and on chemotherapy. In particular, it is unclear whether KRAS mutations are always early events, or could be acquired at later stages of CRC. We report the case of a patient with mCRC, in whom tumor KRAS mutations were acquired after the occurrence of the Wrst metastasis.
Case report
A 35-year-old-female patient, without personal or familial history of cancer, was diagnosed with adenocarcinoma of the transverse colon and synchronous bulky liver metastases. Immunohistochemistry for MLH1, MSH2 and MSH6 on tumor and healthy liver samples revealed no evidence for hereditary non-polyposis colon cancer (HNPCC). She received 8 cycles of a Xuorouracil (5FU) and oxaliplatinbased chronomodulated regimen, which achieved disease stabilization. Irinotecan was added to the regimen for seven cycles, but the patient demonstrated only minor tumor response. A segmental transverse colectomy was then performed, followed by eight cycles of the same triple therapy, but with alternating intravenous (IV) and hepatic arterial infusions (HAI), without any tumor regression. Intravenous cetuximab was therefore added to the previous alternating regimen over 12 additional cycles. This regimen achieved a partial tumor response, associated with grade 2 acneiform rash. The patient could then undergo left hepatectomy and segment VII liver resection. Pathologic examination of the specimen demonstrated viable hepatic metastases with positive surgical margins (R1 resection). Six post-operative cycles of HAI, followed by IV triple therapy associated with IV cetuximab were administered. In spite of continued therapy, new lesions subsequently developed in the liver and the peritoneum. The addition of bevacizumab to the previous regimen did not halt disease progression. Nevertheless, the limited size and number of the progressive lesions prompted a segment V hepatectomy and the resection of both peritoneal nodules. This surgical procedure achieved complete clearance of all macroscopic disease 11 months after the Wrst hepatectomy. The patient received eight post-operative cycles of IV cetuximab and irinotecan/ 5FU for an additional 6 months with no evidence of disease. Two months after chemotherapy discontinuation, new hepatic and peritoneal lesions were discovered. The patient received various palliative irinotecan, Xuoropyrimidine, oxaliplatin, cetuximab, bevacizumab-based regimens resulting at best in stable disease, and Wnally was lost to follow-up in a clinical setting of tumor progression and general status deterioration in July 2008.
Methods
A retrospective analysis of the KRAS mutational status was performed on tissues obtained from the primary tumor and subsequently resected liver metastases. Genomic DNA puriWed from paraYn-embedded tissues was used after histological quantiWcation of tumor tissue in each tumor sample by hematoxylin-eosin-saVron (HES) coloration. The percentage of viable tumor in all the samples analyzed for KRAS mutation varied from 30 to 55% (Table 1 ). The seven KRAS mutations located within codons 12 and 13 were screened using an allelic discrimination assay using primers and speciWc probes for each mutated and non-mutated allele as previously described [6] . BrieXy, reactions were performed in 15 l comprising 20 ng of DNA, 1£ of speciWc primers and probes, and 1£ Taqman Genotyping Master Mix (Applied Biosystems, Foster City, CA). DNA was then submitted to PCR cycle conditions on, and analyzed with a Lightcycler 480 instrument (Roche Applied Science, Mannheim, Germany). The analysis of each sample was performed in duplicate, and DNA from wild-type sample and cell lines exhibiting each KRAS mutations were used as controls in each experiment. The detection threshold of our technique was tested using dilution of DNA bearing the various KRAS mutation into normal DNA using the same methods as for patient samples. All mutations were detectable up to dilution of 1%, except G12V up to 5% and G12S up to 10%. Each sample analysis was performed in duplicate, and wild-type and mutated KRAS controls using DNA extracted from cell lines with known KRAS mutational status were used in each experiment. As shown in Table 1 and Fig. 1 , no mutation in KRAS was detected in the primary colon tumor or in synchronous liver metastasis samples. In contrast, in the metachronous liver metastasis from the second hepatectomy, mutations at codon 13 and 12 were detected in two separate nodules.
We then retrospectively reviewed all other patients with CRC, in whom KRAS was analyzed, using the same technique, in at least two tumor samples from distinct lesions. Thirty-three separate analyses were retrieved from 25 tumor sites in 12 patients (Table 2) . A KRAS mutation was found in eight of nine tumor sites collected in four patients. Three patients with mutated tumor had the same codon 12 mutation in all collected samples (Table 2 ; # 1-3). One patient with a bifocal primary colon tumor had a mutation at codon 13 in only one of them, no mutation in a synchronous liver metastasis and the same mutation in one of two specimens of a subsequent locoregional relapse (Table 2 ; # 4). No acquired mutations were detected in any other patient, beside the current case report. However, only 5 of the 12 patients had KRAS analyzed in metastatic or locoregional recurrences occurring sequentially during disease history, comparable to our case report.
Discussion
Cancer progression is characterized by genomic instability and accumulation of somatic mutations. It is therefore not surprising to observe the development of new mutations during the course of metastatic spread. Nevertheless, KRAS mutations were initially reported as very early events in colorectal carcinogenesis. Even before malignant transformation, about 30-35% of benign colorectal adenomas bear a KRAS mutation, a proportion similar to that observed in invasive cancer [7, 8] . A similar KRAS mutational status was found both in primary tumor and in metastases for more than 90% of the patients with CRC [9] [10] [11] [12] or lung cancer [13, 14] . This Wnding is consistent with KRAS mutations mostly occurring as an early molecular event. However, both studies also document a few cases of KRAS mutations in metastases arising from wt KRAS primary tumors. To the best of our knowledge, we report for the Wrst time a change in KRAS mutational status in two sequential samples of metastatic lesions in the same organ during the course of disease progression.
Evolution of KRAS mutations in this setting might be secondary to clonal selection of cells with early mutated KRAS in a given tumor under pressure from anti-EGFR therapy. This selection would render a previously cetuximab sensitive tumor unresponsive. Alternatively, a novel spontaneous mutation in cancer cells could explain the Wnding of KRAS mutations in metastases, where previously none existed. It is unknown whether exposure to cytotoxic chemotherapy favors KRAS mutation. Neither is it known whether acquired KRAS mutations are observed more frequently in patients with germ-line deWcit in DNA repair systems, such as HNPCC patients. In our patient with an early CRC onset, HNPCC was ruled out, yet no other DNA repair deWciency was sought.
The methodology in this report utilizes a widely accepted technique [5, 6] . The proportion of tumor tissue was appropriate for the technique used to detect gene mutations [4, 5] in our case report (Table 1) , while, among the 
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Normal control D other cases tested, some negative samples had an unknown or insuYcient percentage of tumor cells and may be unreliable (Table 2 , # 6, 9, 12). Furthermore, the sensitivity of our test, measured by a DNA dilution technique, was even higher than that (20%) reported by Lievre et al. [6] . This Wnding may be due to technical diVerences introduced when adapting the method to our local speciWcity. In particular, PCR master mix and PCR instrument were diVerent than those described in the original publication [6] . Furthermore, all specimens were independently tested in duplicate. It is therefore unlikely that the Wnding of a late KRAS mutation would be explained by a false negative result in the samples from the primary tumor and the Wrst hepatectomy. In addition, the clinical course of this patient is consistent with the late change in KRAS status. Albeit heavily exposed to all active drugs used to treat mCRC, only the initial introduction of cetuximab resulted in clinically relevant tumor shrinkage, while the tumor was harboring a wt KRAS gene. Subsequently, the tumor progressed on cetuximab therapy, and tumor tissue from the second hepatectomy showed a mutated KRAS gene. Of note, two diVerent mutations were detected in two separate histological samples, suggesting multiple mutations, or secondary selection of multiple cetuximab-resistant clones during cetuximab therapy.
Intraneoplastic heterogeneity of cancer populations is a well-known phenomenon that could determine the genesis of potential drug-resistant metastatic clones [15] [16] [17] [18] [19] Similarly, tumor heterogeneity is a limit of tumor biomarker analyses [20] , illustrated in our case by the presence of two distinct mutations in two nodules sampled during the same metastatic phase. The lack of KRAS mutations in the initial samples could have been due to sampling in a nonmutated area of the tumor [19] . It is likely that increasing the number of samples analyzed in one tumor location would increase the incidence of discrepant KRAS status. The limits of the conventional technique using DNA extracted from formalin-Wxed tumor samples could be also improved by more sensitive techniques and other DNA source [21] .
Finally, assessment of KRAS status for therapeutic purposes represents a new paradigm in cancer therapy. Our Wndings suggest that a late switch in KRAS mutational status could occur more frequently than currently recognized and account for acquired resistance to anti-EGFR therapies. Progressive metastases unresponsive to treatment do not beneWt from metastasis resection [22] and are usually not resected. KRAS analysis is therefore not available at the time of progression. In this respect, our patient was an [9, 10] . This observation could justify serial assessments of KRAS mutations during the course of CRC in order to adjust therapeutic decisions and treatment strategies, especially in patients with tumor initially bearing wt KRAS. Prospective studies will be necessary to better estimate the incidence of change in KRAS mutational status through the course of metastatic disease and assess their clinical relevance.
